Selling by month
Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.
Disclosed planTo cover taxesOne dollar scale for every month; the tallest bar is labeled
Pattern
What the filings show, past 12 months. Nothing here rates or predicts.
- Sold in 3 of the 13 calendar months from Oct 2025 to Oct 2026: Jan 2026, Feb 2026 and Mar 2026.
- Largest single sale: $747K (2,259 shares) of Alnylam Pharmaceuticals, Inc. on Feb 27, 2026. Filing
- Last sale before this period: Oct 3, 2025.
Roles from filings
Every company we track where this person has filed, newest filing first.
| Company | Title | First filing | Latest filing |
|---|---|---|---|
| Alnylam Pharmaceuticals, Inc. (ALNY) | EVP Chief R&D | Jan 4, 2022 | Mar 6, 2026 |
Recent filings
The last 5 days with transactions, newest first, one line per trade date. Each number links to an SEC filing.
- Mar 5, 2026, Alnylam Pharmaceuticals, Inc.: sold 2,404 shares for $779K, under a disclosed plan. 1 filing: 1
- Mar 4, 2026, Alnylam Pharmaceuticals, Inc.: sold 2,309 shares for $746K, under a disclosed plan. 1 filing: 1
- Mar 3, 2026, Alnylam Pharmaceuticals, Inc.: sold 1,775 shares for $568K, under a disclosed plan. 1 filing: 1
- Mar 2, 2026, Alnylam Pharmaceuticals, Inc.: sold 1,717 shares for $563K, under a disclosed plan; 4,769 shares granted. 1 filing: 1
- Feb 27, 2026, Alnylam Pharmaceuticals, Inc.: sold 4,627 shares for $1.5M, under a disclosed plan; 1,908 shares vested. 1 filing: 1
This page shows only what this person reported on SEC ownership filings. See the methodology. Spotted something wrong? Report an error.